Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02392026 · ClinicalTrials.gov registry record · Phase 4
Safety and Tolerability of Metronidazole Gel 1.3%
A Phase 4 study, sponsored by Insud Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT02392026 is a Phase 4 study that has completed, run by Insud Pharma. The registered enrollment target is 60 participants.
The verdict
NCT02392026, a Phase 4 study, has completed, sponsored by Insud Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
Multicenter, open-label study to evaluate safety and tolerability of Metronidazole Vaginal Gel in females 12 to \<18 years for the treatment of bacterial vaginosis.
Interventions
- DRUG Metronidazole Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-08-12 |
| Est. Completion | 2016-10-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02392026
The ClinicalTrials.gov registry entry for NCT02392026 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insud Pharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metronidazole Gel is the first listed.
NCT02392026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02392026 about?
NCT02392026 is a clinical study titled "Safety and Tolerability of Metronidazole Gel 1.3%". Multicenter, open-label study to evaluate safety and tolerability of Metronidazole Vaginal Gel in females 12 to \<18 years for the treatment of bacterial vaginosis.
What is the current status of trial NCT02392026?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2015-08-12. Estimated completion is 2016-10-05.
What interventions are being tested in trial NCT02392026?
The interventions under investigation include: Metronidazole Gel (DRUG).
Who is sponsoring clinical trial NCT02392026?
This trial is sponsored by Insud Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.